Literature DB >> 7523212

TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.

R Hamelin1, J F Fléjou, F Muzeau, F Potet, P Laurent-Puig, F Fékété, G Thomas.   

Abstract

BACKGROUND/AIMS: Limited data are available regarding TP53 gene alterations in Barrett's esophagus. This study was undertaken to characterize TP53 mutations and p53 protein immunoreactivity in cancers and preinvasive lesions of Barrett's esophageal mucosa.
METHODS: Seventeen Barrett's adenocarcinomas were examined by polymerase chain reaction amplification, denaturant gradient gel electrophoresis, and sequencing for the presence of TP53 mutations in exons 5-8. In 9 cases, Barrett's epithelium adjacent to the cancer was investigated. p53 protein immunoreactivity was studied with PAb 1801.
RESULTS: Sixteen mutations were found in 15 adenocarcinomas, including 10 missense, 3 nonsense, 1 frameshift, and 2 mutations located within consensus splice donor and acceptor sequences. All nucleotide substitutions were transitions. Eight of the 12 transitions involving a GC base pair occurred within the context of a CpG dinucleotide. p53 immunostaining was present in all 10 cases with missense mutations and in 1 case without a detectable mutation. The surrounding Barrett's mucosa showed TP53 mutations identical to that observed in the carcinoma in only 3 of 5 specimens showing high-grade dysplasia.
CONCLUSIONS: TP53 gene mutations and p53 protein immunostaining are present in a majority of Barrett's adenocarcinomas. Our results suggest that these mutations are involved at an early stage during malignant transformation of Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523212     DOI: 10.1016/0016-5085(94)90225-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  51 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 2.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 3.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

4.  Infrequent p53 gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Chang-Ping Li; Naoko Iida; Hideaki Oda; Shigetoshi Aiso; Takatoshi Ishikawa
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 5.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 6.  Screening and surveillance for Barrett's esophagus: current issues and future directions.

Authors:  Sung E Choi; Chin Hur
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

7.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

8.  Claudin expression in Barrett's esophagus and adenocarcinoma.

Authors:  Hajnalka Gyõrffy; Agnes Holczbauer; Pál Nagy; Zsuzsa Szabó; Péter Kupcsulik; Csilla Páska; János Papp; Zsuzsa Schaff; András Kiss
Journal:  Virchows Arch       Date:  2005-08-30       Impact factor: 4.064

9.  p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.

Authors:  A G Casson; M Tammemagi; S Eskandarian; M Redston; J McLaughlin; H Ozcelik
Journal:  Mol Pathol       Date:  1998-04

10.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.